| 58.59 Delayed Data As of Nov 15 |  +0.08 / +0.14%Today’s Change | 42.48 Today|||52-Week Range 59.18 | +12.72% Year-to-Date |
| Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better Nov 12 / MotleyFool.com - Paid Partner Content | How Sweet Were Nektar Therapeutics' Q3 Results? Nov 07 / MotleyFool.com - Paid Partner Content |
| Why Bristol-Myers Squibb Stock Gained 13% in October Nov 11 / MotleyFool.com - Paid Partner Content | Buy These 2 Stocks to Access China's Huge Healthcare Market Nov 06 / MotleyFool.com - Paid Partner Content |
| Better Buy: Biogen vs. Celgene Nov 10 / MotleyFool.com - Paid Partner Content | Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results? Nov 04 / MotleyFool.com - Paid Partner Content |
| Previous close | 58.51 |
| Today’s open | 58.54 |
| Day’s range | 58.40 - 58.79 |
| Volume | 9,725,844 |
| Average volume (3 months) | 11,968,412 |
| Market cap | $95.5B |
| Earnings growth (last year) | +393.92% |
| Earnings growth (this year) | +9.09% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +8.59% |
| P/E ratio | 16.9 |
| Price/Sales | 3.77 |
| Price/Book | 6.78 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVONovo Nordisk | -0.61 | -1.05% |
| LLYEli Lilly and Co | +1.80 | +1.62% |
| GSKGlaxoSmithKline | +0.24 | +0.55% |
| CELGCelgene | 0.00 | 0.00% |
| Next reporting date | January 27, 2020 |
| EPS forecast (this quarter) | $0.92 |
| Annual revenue (last year) | $22.6B |
| Annual profit (last year) | $4.9B |
| Net profit margin | 21.81% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
